Over the past decade, significant advancements have been made in the development of anti-obesity therapies, particularly with the emergence of the incretin-mimetic therapies, such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Here, GLP1R is linked to obesity disorder.